Research Article

Expression and significance of plasma 3-NT and ox-LDL in patients with Alzheimer's disease

Published: October 20, 2014
Genet. Mol. Res. 13 (4) : 8428-8435 DOI: 10.4238/2014.October.20.19

Abstract

To examine the expression and clinical significance of plasma 3-nitrotyrosine (3-NT) and oxidized low-density lipoprotein (ox-LDL) levels in patients with Alzheimer's disease (AD), we examined 48 AD patients and 37 healthy control subjects. The Mini-Mental State Examination, Activities of Daily Living Scale, and Hachinski Ischemic Scale were examined in all subjects. AD patients were classified using the Global Deterioration Scale. The concentrations of plasma 3-NT and ox-LDL were detected using an enzyme-linked immunosorbent assay. We found that the plasma 3-NT concentration in the AD group (119.46 ± 21.82 nM) was significantly higher than that in the control group (55.09 ± 9.63 nM) (P

To examine the expression and clinical significance of plasma 3-nitrotyrosine (3-NT) and oxidized low-density lipoprotein (ox-LDL) levels in patients with Alzheimer's disease (AD), we examined 48 AD patients and 37 healthy control subjects. The Mini-Mental State Examination, Activities of Daily Living Scale, and Hachinski Ischemic Scale were examined in all subjects. AD patients were classified using the Global Deterioration Scale. The concentrations of plasma 3-NT and ox-LDL were detected using an enzyme-linked immunosorbent assay. We found that the plasma 3-NT concentration in the AD group (119.46 ± 21.82 nM) was significantly higher than that in the control group (55.09 ± 9.63 nM) (P